China's Neuracle Files for Shanghai IPO, Seeking RMB 2.5 Billion
The Shanghai Stock Exchange accepted an IPO application from Neuracle, which is seeking RMB 2.5 billion for BCI product development, industrialization and working capital. The filing shows an established non-invasive neurophysiology equipment business alongside invasive products that still require clinical, regulatory and commercialization spending. Acceptance starts the review process and is not approval to list.